The Next Steps

in Tackling

Sarcopenic Obesity

The problem

Fat mass up. Muscle mass down. Why this combination is a red flag.

Most people think of obesity and muscle loss as separate problems. But sarcopenic obesity (SO) – the coexistence of excess body fat and reduced muscle mass, strength, and quality – combines both into a condition that amplifies the risk of each.

And it’s not just an older adult problem. Emerging research now links SO to insulin resistance and heightened metabolic risk in much younger cohorts (including children and adolescents), driven by sedentary lifestyles, poor diet, and hormonal shifts during puberty.

Depending on the population studied and the definition used, SO affects anywhere from 0% to 41% of people – a staggeringly wide range that highlights just how much clarity is still needed in this field.

The mechanisms

What's going on inside the body?

The biology of SO is a vicious cycle. Age-related metabolic changes and excess fat tissue trigger chronic low-grade inflammation. That inflammation accelerates muscle breakdown. Less muscle means slower metabolism, which promotes more fat storage – and around it goes.

Some of the most important – and least understood – mechanisms currently under investigation include:

  • Hormonal status
  • Mitochondrial function
  • Neuromuscular junction efficiency
  • Bone–muscle–fat interactions
  • Sex differences in physiology
  • Daily energy expenditure
  • Adipose tissue metabolism

Understanding these mechanisms – especially in younger cohorts – is now a global research priority. It’s where the next big breakthroughs are likely to come from.

Early detection

Catching it before it catches you.

Timing matters. Standardised screening – from simple anthropometric measurements to DXA scans and CT imaging – can identify SO early, when intervention is most effective. But high-tech tools aren’t always accessible.

That’s why there’s growing excitement around blood-based biomarkers (muscle-specific proteins, inflammatory markers) and advanced multi-omics approaches combining genomics, proteomics, and AI-driven analytics. These tools could make personalised, early-stage diagnosis a realistic prospect for far more people.

Interventions

What actually works?

Exercise: Resistance, aerobic, and combined training all show benefits. Blood flow restriction (BFR) training is an emerging option, especially for those unable to lift heavy loads.

Nutrition: Adequate protein is foundational. But pairing it with Vitamin D, omega-3s, and strategic caloric approaches may be even more effective than protein alone.

Pharmacology: Testosterone, myostatin inhibitors, and growth hormone therapy are established tools – particularly useful when lifestyle changes alone aren’t sufficient.

AI & Technology: Machine learning tools are beginning to identify at-risk individuals earlier and guide truly personalised treatment plans based on genetics, lifestyle, and history.

The bigger picture

Prevention isn't just better than cure - it's fairer, too.

Treating SO once it takes hold requires a complex, costly combination of medical care, physical therapy, and sustained lifestyle change. Prevention – through regular physical activity, balanced nutrition, and adequate muscle-building habits – is dramatically more effective and far less burdensome on individuals and healthcare systems alike.

But there’s an equity dimension here that cannot be ignored. SO disproportionately affects people from lower socioeconomic backgrounds, where access to healthy food, safe exercise spaces, and quality healthcare is limited. Any meaningful prevention strategy must address these structural barriers – not just individual behaviour.

The bottom line: Sarcopenic obesity is a complex, underrecognized condition that is catching researchers, clinicians, and the general public off guard – and it’s no longer just a problem for older adults. Building and maintaining muscle throughout life isn’t just about performance. It may be one of the most important things you can do for your long-term metabolic health.

Here are a few pieces worth reading.

  • Scott D, Hirani V. Sarcopenic obesity. European Geriatric Medicine. 2016;7(3):214-9. 

  • Jayasinghe S, Hills AP. Sarcopenia, obesity, and diabetes-The metabolic conundrum trifecta. Diabetes & Metabolic Syndrome. 2022;16(11):102656-.

  • Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature Reviews Endocrinology. 2018;14(9):513-37.

  • Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity-definition, etiology and consequences. Current opinion in clinical nutrition and metabolic care. 2008;11(6):693.

  • Cauley JA. An overview of sarcopenic obesity. Journal of Clinical Densitometry. 2015;18(4):499-505.

  • Zembura M, Matusik P. Sarcopenic Obesity in Children and Adolescents: A Systematic Review. Frontiers in Endocrinology. 2022;13.